A scientific statement of AHA on amyloidosisNews - July 13, 2020
On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, a scientific statement was recently published in Circulation titled ‘’Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association”. This statement is intended to guide clinical practice and facilitate management of patients by covering diagnostic strategies, including a testing algorithm, and management options. In addition, areas of uncertainty and future investigation are addressed.
Enthusiasm about ATTR-CM has increased, because of progress made in three areas. Imaging techniques have resulted in accurate noninvasive diagnosis, observational studies indicate underrecognition of ATTR-CM in patients with heart failure, and therapies are now approved for treatment of ATTR-CM.